Orthocell (ASX:OCC) Insider Michael McNulty Acquires 24,561 Shares of Stock

Orthocell Limited (ASX:OCC) insider Michael McNulty bought 24,561 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was acquired at an average cost of A$1.14 per share, for a total transaction of A$27,974.98.

Orthocell Stock Performance

The stock has a market cap of $375.52 million, a PE ratio of -42.23 and a beta of 1.16. The company has a debt-to-equity ratio of 15.22, a quick ratio of 5.07 and a current ratio of 4.34.

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries.